Two case reports of symptomatic visceral leishmaniasis in AIDS patients concomitant immune reconstitution due to antiretroviral therapy

Scandinavian Journal of Infectious Diseases

Volumn 36, Issue 3, 2004, Pages 225-227

  Berry, Antoine ^a,c   Abraham, Bruno ^a   Dereure, Jacques ^b   Pinzani, Veronique ^a   Bastien, Patrick ^b   Reynes, Jacques ^a  

^a GUI DE CHAULIAC HOSPITAL   (France)

^b Laboratoire de Parasitologie   (France)

^c CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPHOTERICIN B DEOXYCHOLATE; ANTIRETROVIRUS AGENT; CD4 ANTIGEN; DIDANOSINE; HYDROXYUREA; INDINAVIR; LOPINAVIR; STAVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; BONE MARROW BIOPSY; CASE REPORT; CAUCASIAN; CONVALESCENCE; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOELECTROPHORESIS; IMMUNOFLUORESCENCE; IN VITRO STUDY; LEISHMANIA; MALE; POLYMERASE CHAIN REACTION; SYMPTOM; TOXIC HEPATITIS; VISCERAL LEISHMANIASIS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANIMALS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOCOMPROMISED HOST; LEISHMANIASIS, VISCERAL; MALE; MIDDLE AGED; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX;

EID: 2442571045     PISSN: 00365548     EISSN: None     Source Type: Journal    
DOI: 10.1080/00365540410019426     Document Type: Article

References (15)

1. Jacobson MA, Zegans M, Pavan PR, O'Donnell JJ, Sattler F, Rao N, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349: 1443-5.
2. Race EM, Adelson-Mitty J, Kriegel GR, Barlam TF, Reimann KA, Letvin NL, Japour AJ. Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease. Lancet 1998; 351:252-5.
3. Narita M, Ashkin D, Hollender ES, Pitchenik AE. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med 1998; 158: 157-61.
4. Albrecht H. Leishmaniasis: new perspectives on an under-appreciated opportunistic infection. AIDS 1998; 12: 2225-6.
5. Pineda JA, Gallardo JA, Macias J, Delgado J, Regordan C, Morillas F, et al. Prevalence of factors associated with visceral leishmaniasis in human immunodeficiency virus type 1-infected patients in southern Spain. J Clin Microbiol 1998; 39: 2419-22.
6. Kubar J, Marty P, Lelièvre A, Quaranta JF, Caroli-Bosc C, Le Fichoux Y. Visceral leishmaniasis in HIV-positive patients: primary infection, reactivation and latent infection. Impact of the CD4+ T-lymphocyte counts. AIDS 1998; 12: 2147-53.
7. Cozon G, Grenland T, Revillard JP. Profound CD4 + lymphocytopenia in the absence of HIV infection in a patient with visceral leishmaniasis. N Engl J Med 1990; 332: 132.
8. Berhe N, Wolday D, Hailu A, Abraham Y, Ali A, Gebre-Michael T, et al. HIV viral load and response to antileishmanial chemotherapy in co-infected patients. AIDS 1999; 13: 1921-5.
9. Bernier R, Turco SJ, Olivier M, Tremblay M. Activation of human immunodeficiency virus type 1 in monocytoid cells by the protozoan parasite Leishmania donovani. J Virol 1998; 69: 7282-5.
10. Michelet C, Arvieux C, Frano̧is C, Besnier JM, Rogez JP, Breux JP, et al. Opportunistic infection occurring during highly active antiretroviral treatment. AIDS 1998; 12: 1815-22.
11. de la Rosa R, Pineda JA, Delgado J, Macias J, Morillas F, Martin-Sanchez J, et al. Influence of highly active antiretroviral therapy on the outcome of subclinical visceral leishmaniasis in human immunodeficiency virus-infected patients. Clin Infect Dis 2001; 32: 633-5.
12. Gazzinelli RT, Makino M, Chattopadhyay SK, Snapper CM, Sher A, Hugin AW, Morse HC. 3rd. CD4+ subset regulation in viral infection. Preferential activation of Th2 cells during progression of retrovirus-induced immunodeficiency in mice. J Immunol 1992; 148: 182-8.
13. Zwingenberger K, Harms G, Pedrosa C, Omena S, Sandkamp B, Neifer S. Determinants of immune response in visceral leishmaniasis: evidence for predominance of endogenous interleukin 4 over interferon-gamma production. Clin Immunol Immunopathol 1990; 57: 242-9.
14. Kelleher AD, Al-Harthi L, Landay AL. Immunological effects of antiretroviral and immune therapies for HIV. AIDS 1997; 11 (Suppl A): S149-55.
15. Imami N, Antonopoulos C, Hardy GA, Gazzard B, Gotch FM. Assessment of type 1 and type 2 cytokines in HIV type 1-infected individuals: impact of highly active antiretroviral therapy. AIDS Res Hum Retroviruses 1999; 15: 1799-808.